This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
ATLANTA ― Deep transcranial magnetic stimulation (dTMS), already approved for treatment-resistant depression, is proving beneficial for obsessive compulsive disorder (OCD), adult attention- deficit/hyperactivity disorder (ADHD), and other psychiatric conditions, according to new research.
The success of the technology depends on targeting the most appropriate brain regions, the research suggests.
Results from some of these new studies were presented here at American Psychiatric Association (APA) 2016 Annual Meeting.
Read the aricle here.